TOKYO — September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd.
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in